November 15, 2025 — Anyone who thought this would be a passing thing was way off the mark. As prices of GLP-1 medicines are falling, their use is rising. As Stat News notes, we now have more people using these medicines than the entire population of Texas. This rising trend occurs against a background of costs that are still […]
November 3, 2025 — A year ago, we had these wonderful new obesity medicines – semaglutide and tirzepatide – and nobody could get them. Demand had outstripped supply and we had a shortage. Earlier this year, the supply shortage for both drugs resolved, but now we face the same situation because of a different shortage. There is a shortage […]
October 22, 2025 — We are most accustomed to technology bringing economic disruption. Three decades ago, it was the internet. Then smartphones and social media. Now, we obsess about the effects of artificial intelligence. But a strong case is building that obesity medicine is becoming an economic disruptor on a scale that is equal or greater than any of […]
October 21, 2025 — The acute shortage of obesity medicines is over. But in absolute terms we are still operating with a mindset of scarcity when thoughts turn to obesity care. Policy often dictates limited access to care and even more so, to medicines that can so effectively treat this condition. What happens if we start thinking in terms […]
October 14, 2025 — At FNCE yesterday, the Weight Management practice group presented the changing role of dietitians in weight management with remarkable clarity – something GLP-1s are bringing at a dizzying pace. Colleen Tewksbury summed up the very essence of this change, saying: “We are shifting the focus from quantity to quality of nutrition in weight management.” It […]
October 12, 2025 — Honestly, there is so much glaring, blinding irony in the news these days that this one almost slipped by us. Costco makes its money from selling people ginormous packs of food, but now the chain is getting into the action on GLP-1s by selling them at the discounted price of $499 per month. Both Ozempic […]
October 11, 2025 — In the International Journal of Obesity, obesity medicine physician and researcher Caroline Apovian offers a compelling case to favor a prediabetes indication for GLP-1s. She writes: “The approval of a GLP-1 for prediabetes will change the landscape for prevention of T2DM and its complications due to early detection. Currently, most individuals at risk of T2DM […]
September 28, 2025 — Back in March 2024, we welcomed the news of a door opening ever so slightly for Medicare Part D plans to cover GLP-1s in people with obesity and heart disease. So 18 months later, it’s reasonable to ask, how’s that working out for everyone? A new research letter in JAMA gives us an answer, but […]
September 17, 2025 — Today at EASD, investigators for the ATTAIN-1 pivotal phase three trial are presenting detailed results for orforglipron in obesity. These results, published yesterday in the New England Journal of Medicine, offer no big surprises. The effectiveness in this 72-week trial was acceptable. But a big question hangs in the air. Will orforglipron be the GLP-1 […]
September 16, 2025 — Today in Nature Medicine, compelling new research tells that long-term outcomes with metabolic surgery are superior to the outcomes with GLP-1 agonists in persons with diabetes and obesity. These are impressive and important results. But we have to wonder if anyone is really listening. The enthusiasm for advanced obesity medicines is so great that many […]
